Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Tjarko Meijerhof"'
Autor:
Yoshita Bhide, Wei Dong, Tjarko Meijerhof, Jacqueline deVries‐Idema, Hubert G. Niesters, Anke Huckriede
Publikováno v:
Immunity, Inflammation and Disease, Vol 8, Iss 3, Pp 279-291 (2020)
Abstract Introduction Cotton rats are a suitable model for the study of influenza disease symptoms and responses to influenza vaccination. We have previously shown that two immunizations with 15 µg whole inactivated virus (WIV) influenza vaccine cou
Externí odkaz:
https://doaj.org/article/e4d62379fd144d6dbb9c87d798cb2997
Autor:
Martin van Eijk, Marine L. B. Hillaire, Guus F. Rimmelzwaan, Michael J. Rynkiewicz, Mitchell R. White, Kevan L. Hartshorn, Martin Hessing, Peter A. Koolmees, Monique H. Tersteeg, Maarten H. van Es, Tjarko Meijerhof, Anke Huckriede, Henk P. Haagsman
Publikováno v:
Frontiers in Immunology, Vol 10 (2019)
Innate immunity is critical in the early containment of influenza A virus (IAV) infection and surfactant protein D (SP-D) plays a crucial role in innate defense against IAV in the lungs. Multivalent lectin-mediated interactions of SP-D with IAVs resu
Externí odkaz:
https://doaj.org/article/0c84c4792fb344a28f97b08f77a05c7a
Autor:
Yoshita Bhide, Wei Dong, Inta Gribonika, Daniëlle Voshart, Tjarko Meijerhof, Jacqueline de Vries-Idema, Stephen Norley, Kate Guilfoyle, Sarah Skeldon, Othmar G. Engelhardt, Louis Boon, Dennis Christensen, Nils Lycke, Anke Huckriede
Publikováno v:
Frontiers in Immunology, Vol 10 (2019)
Adjuvanted whole inactivated virus (WIV) influenza vaccines show promise as broadly protective influenza vaccine candidates. Using WIV as basis we assessed the relative efficacy of different adjuvants by carrying out a head-to-head comparison of the
Externí odkaz:
https://doaj.org/article/87556b2c48d6402581080a16c5962737
Autor:
Wei Dong, Yoshita Bhide, Federica Sicca, Tjarko Meijerhof, Kate Guilfoyle, Othmar G. Engelhardt, Louis Boon, Cornelis A. M. de Haan, George Carnell, Nigel Temperton, Jacqueline de Vries-Idema, David Kelvin, Anke Huckriede
Publikováno v:
Frontiers in Immunology, Vol 9 (2018)
Sequential infection with antigenically distinct influenza viruses induces cross-protective immune responses against heterologous virus strains in animal models. Here we investigated whether sequential immunization with antigenically distinct influen
Externí odkaz:
https://doaj.org/article/a54aaa346b5548be80e650c96533d556
Autor:
Stephanie van de Wall, Mateusz Walczak, Nienke van Rooij, Baukje-Nynke Hoogeboom, Tjarko Meijerhof, Hans W. Nijman, Toos Daemen
Publikováno v:
Vaccines, Vol 3, Iss 2, Pp 221-238 (2015)
The skin is an attractive organ for immunization because of the presence of antigen-presenting cells. Intradermal delivery via tattooing has demonstrated superior vaccine immunogenicity of DNA vaccines in comparison to conventional delivery methods.
Externí odkaz:
https://doaj.org/article/16d3a377a40e4e5a9d935b562174666a
Autor:
Harshad P. Patil, José Herrera Rodriguez, Jacqueline de Vries-Idema, Tjarko Meijerhof, Henderik W. Frijlink, Wouter L. J. Hinrichs, Anke Huckriede
Publikováno v:
Vaccines, Vol 5, Iss 3, p 19 (2017)
Adjuvants are key components in vaccines, they help in reducing the required antigen dose but also modulate the phenotype of the induced immune response. We previously showed that GPI-0100, a saponin-derived adjuvant, enhances antigen-specific mucosa
Externí odkaz:
https://doaj.org/article/b6b0f2c48095449f8125a519889b7a19
Autor:
Natalija Budimir, Aalzen de Haan, Tjarko Meijerhof, Simke Waijer, Louis Boon, Emma Gostick, David A Price, Jan Wilschut, Anke Huckriede
Publikováno v:
PLoS ONE, Vol 8, Iss 5, p e63163 (2013)
Current influenza vaccines fail to induce protection against antigenically distinct virus strains. Accordingly, there is a need for the development of cross-protective vaccines. Previously, we and others have shown that vaccination with whole inactiv
Externí odkaz:
https://doaj.org/article/7f9759a548894f2180e67579b2ec157b
Publikováno v:
PLoS ONE, Vol 8, Iss 4, p e61287 (2013)
INTRODUCTION: RSV infection remains a serious threat to newborns and the elderly. Currently, there is no vaccine available to prevent RSV infection. A mucosal RSV vaccine would be attractive as it could induce mucosal as well as systemic antibodies,
Externí odkaz:
https://doaj.org/article/207c966ec4bb4b32a9e274ec64a3e67b
Autor:
Natalija Budimir, Anke Huckriede, Tjarko Meijerhof, Louis Boon, Emma Gostick, David A Price, Jan Wilschut, Aalzen de Haan
Publikováno v:
PLoS ONE, Vol 7, Iss 1, p e30898 (2012)
BACKGROUND: The inability of seasonal influenza vaccines to effectively protect against infection with antigenically drifted viruses or newly emerging pandemic viruses underlines the need for development of cross-reactive influenza vaccines that indu
Externí odkaz:
https://doaj.org/article/19ad40b9d2e5421fa8d48051ec3db34e
Autor:
Tobias Kamphuis, Tjarko Meijerhof, Toon Stegmann, Julia Lederhofer, Jan Wilschut, Aalzen de Haan
Publikováno v:
PLoS ONE, Vol 7, Iss 5, p e36812 (2012)
Respiratory Syncytial Virus (RSV) is a major cause of viral brochiolitis in infants and young children and is also a significant problem in elderly and immuno-compromised adults. To date there is no efficacious and safe RSV vaccine, partially because
Externí odkaz:
https://doaj.org/article/ab456c92be0c4416a19182e8509f692b